Lissette Machin, MD
Obstetrics & Gynecology · Pinehurst, NCNPI 1033144357
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 215 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Novo Nordisk at 24.8% of the total. Reporting peaked in 2022 at $1,164 and has fallen 52.1% since, to $557 in 2025. Among obstetrics & gynecology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Astellas Pharma US Inc$471
- Daiichi Sankyo Inc.$332
- Aspira Women's Health Inc$249
- Organon$147
- plus $1K from 29 others
What the payments were for
- Food & beverage$4,86997%
- Education$1613%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $1,248 |
| AbbVie | 45 | $1,094 |
| Astellas Pharma US Inc | 15 | $471 |
| Daiichi Sankyo Inc. | 19 | $332 |
| Aspira Women's Health Inc | 3 | $249 |
| Organon | 9 | $147 |
| Intuitive Surgical | 2 | $144 |
| Pfizer | 9 | $140 |
| Laborie Medical Technologies Corp. | 1 | $123 |
| Axonics, Inc. | 1 | $106 |
| Mayne Pharma Commercial LLC | 5 | $101 |
| Therapeuticsmd, Inc. | 5 | $83 |
| Exeltis, USA Inc. | 4 | $81 |
| Coopersurgical, Inc. | 4 | $71 |
| Lilly USA, LLC | 4 | $68 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| Bayer | 5 | $62 |
| Evofem Biosciences, Inc. | 3 | $45 |
| Urovant Sciences Inc | 3 | $42 |
| Hologic Sales And Service, LLC | 3 | $41 |
| Shield Therapeutics Inc | 2 | $38 |
| AMAG Pharmaceuticals, Inc. | 2 | $32 |
| Agile Therapeutics, Inc. | 2 | $32 |
| Lupin Inc. | 2 | $29 |
| Duchesnay USA Incorporated | 2 | $26 |
| Smith+Nephew | 2 | $25 |
| Coloplast | 1 | $16 |
| Mylan Pharmaceuticals Inc. | 1 | $16 |
| Avion Pharmaceuticals | 1 | $16 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Amgen | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Millicent US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$476
- Wegovy$250
- OVA1$184
- Da Vinci Surgical System$125
- Veozah$125
- Orilissa$109
- Axonics r-SNM System$106
How this compares
$5,031 in reported general payments places this provider in the 90th percentile of 1,344 obstetrics & gynecology providers in North Carolina.
See all obstetrics & gynecology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 24 | $24,188 |
| MyrbetriqMirabegron | 21 | $12,230 |
| VeozahFezolinetant | 11 | $5,814 |
| Estradiol | 73 | $3,819 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 13 | $3,115 |
| Estradiol (Twice Weekly)Estradiol | 22 | $2,697 |
| ProgesteroneProgesterone, Micronized | 28 | $1,263 |
| ValacyclovirValacyclovir Hcl | 22 | $649 |
| Nystatin | 19 | $181 |
| Metronidazole | 14 | $148 |
| Fluconazole | 17 | $84 |
| Clonidine Hcl | 16 | $41 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $65 | $24,18824 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $471 | $18,04432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,344 obstetrics & gynecology providers in North Carolina.
Other obstetrics & gynecology in Pinehurst
- Stephen SzaboPinehurst$80K
- Jerry MatkinsCharlotte$481K
- Laura McKainWilmington$475K
- Leslie Hansen-LindnerCharlotte$372K
- Robin MatthewsClyde$217K
- Haywood BrownDurham$165K
- Jack IngeRaleigh$157K
- Geeta SwamyDurham$142K
- Karie LafleurAsheville$135K
- Ty RobinsonHigh Point$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.